PDL BioPharma (PDLI) Misses Q4 EPS by 15c, Authorizes Repurchase of $30M In Common Stock Through March 2018

PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of ($0.06), $0.15 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $66.5 million versus the consensus estimate of $56.37 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance